Amundi Raises Stock Position in Hologic, Inc. $HOLX

Amundi lifted its stake in Hologic, Inc. (NASDAQ:HOLX) by 2.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,111,904 shares of the medical equipment provider’s stock after purchasing an additional 26,970 shares during the period. Amundi owned 0.50% of Hologic worth $72,607,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Chung Wu Investment Group LLC bought a new position in shares of Hologic in the 2nd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd grew its stake in Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the period. Loomis Sayles & Co. L P bought a new position in Hologic in the second quarter worth $33,000. Zions Bancorporation National Association UT purchased a new position in Hologic during the first quarter valued at $34,000. Finally, Cromwell Holdings LLC boosted its holdings in shares of Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 436 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the subject of several recent research reports. BNP Paribas Exane lowered shares of Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 target price for the company. in a report on Friday, November 21st. Raymond James Financial downgraded Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Argus boosted their target price on Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Finally, Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Five investment analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, Hologic has a consensus rating of “Hold” and an average price target of $79.67.

Insider Buying and Selling

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.88% of the stock is currently owned by corporate insiders.

Hologic Trading Down 0.2%

Shares of HOLX stock opened at $74.85 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. The company has a market cap of $16.68 billion, a price-to-earnings ratio of 30.18, a PEG ratio of 2.13 and a beta of 0.70. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $80.31. The firm has a fifty day moving average price of $72.43 and a 200-day moving average price of $67.91.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping the consensus estimate of $1.10 by $0.03. The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.01 earnings per share. As a group, equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.